Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Tivdak (tisotumab vedotin-tftv) is an antibody-drug conjugate approved by the FDA for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Tivdak combines a monoclonal antibody targeting tissue factor, a protein highly expressed on cervical cancer cells, with a potent chemotherapy payload (monomethyl auristatin E). Once bound to tissue factor, Tivdak is internalized by the cancer cell, releasing the payload to induce cancer cell death.
Tivdak is intended for patients with recurrent or metastatic cervical cancer whose disease has progressed despite prior chemotherapy treatment.
The recommended dose of Tivdak is 2 mg/kg (up to a maximum of 200 mg) administered as an intravenous infusion over 30 minutes, every 3 weeks, until disease progression or unacceptable toxicity.
Boxed Warning — Tivdak: Tivdak can cause severe ocular toxicities, resulting in changes in vision, including severe vision loss, and corneal ulceration. Patients should undergo an ophthalmic examination before starting treatment, before each dose, and as clinically indicated.
Patients should use lubricating and vasoconstrictive eye drops, cooling eye pads during infusion, and avoid contact lenses during treatment unless directed otherwise by an ophthalmologist.
Peripheral neuropathy has been reported. Patients should be monitored for symptoms such as numbness, tingling, or weakness, with dose modification as needed.
Bleeding events, including serious cases, have occurred. Patients should be monitored for signs of hemorrhage during treatment.
Severe or fatal pneumonitis and severe cutaneous reactions, including Stevens-Johnson syndrome, have been reported and require prompt evaluation.
Tivdak may cause fetal harm. Effective contraception should be used during treatment and for a period after the final dose, as advised by the treating physician.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Tivdak is manufactured and marketed by Seagen Inc. and Genmab US, Inc. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating gynecologic oncologist confirming cervical cancer diagnosis and prior chemotherapy history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for recurrent or metastatic cervical cancer, Tivdak is sourced through authorized channels and imported under GDP-compliant, cold-chain logistics to preserve product quality throughout transit.
NPP sources Tivdak directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Tivdak requires refrigerated storage at 2°C to 8°C, protected from light. NPP maintains a continuous, monitored cold chain throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile cold-chain logistics to the patient's city.
Patients across India can access Tivdak through NPP's regulated import pathway, with gynecologic oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support gynecologic oncology care coordination and documentation for Tivdak access.
Delhi's major hospitals assist patients with prescription support and documentation for Tivdak.
Bangalore's specialist network offers access coordination for eligible cervical cancer patients seeking Tivdak.
Chennai-based oncology specialists coordinate Tivdak access alongside comprehensive cervical cancer care.
Hyderabad's care institutions support patients pursuing Tivdak therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Tivdak.
Pune-based specialists assist with prescription support and Tivdak treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Tivdak.
Kochi's specialist units assist patients with the documentation needed for Tivdak access.
Chandigarh's care centers support Tivdak treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Tivdak access process.
Lucknow-based centers assist patients pursuing Tivdak therapy.
Bhubaneswar's institutions support access to Tivdak for eligible patients.
Guwahati's specialists help coordinate Tivdak access for patients across the Northeast.
Patients in other cities across India can also access Tivdak through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
